Femasys Locks Down Key Patents and Fresh Cash — But Can a Micro-Cap Birth Control Startup Translate IP Into Revenue?

Shares of Femasys jumped 14% to $2.68 after the Atlanta-based women's health company disclosed new U.S. and international patents covering the core blended-polymer material in its non-surgical permanent birth control product. The announcement follows a turbulent stretch that has seen the stock swing from near-delisting to a flurry of capital raises and regulatory wins — raising a central question: is this micro-cap finally building a real foundation, or just stringing together catalysts?

• The Patents Shield the Product's Secret Ingredient, Not Just the Device. Femasys announced the issuance of patents in the United States and key international markets specifically covering the blended-polymer component — the material inserted into fallopian tubes to achieve permanent contraception. Previous patents protected only the delivery system. That distinction matters: competitors could theoretically design around a device patent, but material-composition patents are harder to replicate. The U.S. patent is expected to remain in effect until at least 2039, strengthening the intellectual property portfolio of Femasys's flagship product, which is currently in the pivotal phase of clinical trials.

• $30 Million Just Hit the Bank — With Up to $60 Million More on the Table. Femasys closed a $30 million private placement led by new institutional investor Nantahala Capital, with participation from Rosalind Advisors and members of management.

Accompanying warrants carry a $2.95 exercise price and a three-year term; if fully exercised for cash, they could provide up to an additional $60 million. That runway is critical for a company that generated just $2.29 million in 2025 revenue while posting losses of $18.63 million.

• The Stock Nearly Lost Its Nasdaq Listing Weeks Ago. Femasys executed a 1-for-20 reverse stock split in early June and only regained compliance with Nasdaq's minimum bid price rule on June 24. The reverse split, while cosmetically boosting the price, dramatically shrunk the share count. Investors should note the stock traded as low as $0.38 in May before the split.

• Approvals Exist Abroad, but the Big Prize Is Still Years Away. FemBloc received full regulatory approval in Europe in June 2025, the UK in August 2025, and New Zealand in September 2025.

The company is conducting the FINALE pivotal trial for U.S. FDA approval — the market that would truly move the revenue needle. Until that trial reads out, Femasys remains a pre-revenue bet dressed up with fresh IP and institutional backing.